0 SBIs occurred in any patient during the 52-week efficacy study period1
0 withdrawals due to adverse reactions in the phase 3 pivotal and extension studies1
Eligible patients may pay as little as $0 for cutaquig¶
Hear from John, a patient with PI, about his path to SCIg therapy and how cutaquig helped him
Interactive calculator to determine a patient's dose, number of sites, and approximate time to complete infusion
Watch cutaquig videos and access educational resources and tools for patients
View materials for you and patients using cutaquig
Find videos and on-demand webinars
View materials for you and patients using cutaquig
CUTAQUIG (Immune Globulin Subcutaneous [Human] - hipp) is a 16.5% immune globulin solution for subcutaneous infusion (IGSC), indicated as replacement therapy for primary humoral immunodeficiency (PI) in adults and pediatric patients 2 years of age and older. This includes, but is not limited to, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.
Please see Full Prescribing Information, including BOXED WARNING and Patient Information and Instructions for Use.